Clinical Trials Download Epilepsy Medicine 
Cannabis Law Report
NOVEMBER 24, 2019
Cannabis-based medicinal products. Severe treatment-resistant epilepsy. Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy. NICE guideline [NG144] Published date: November 2019. Chronic pain.
Project CBD
FEBRUARY 28, 2023
The following excerpt analyzes CBD marketing trends reported by the American Botanical Council, a membership organization that educates consumers, health care professionals, journalists, and others about the safe and effective use of medicinal plants. Available at: www.fda.gov/media/131878/download. Epilepsy Behav. 2021.108514.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 24, 2021
Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Focusing on professional medical publications, this study sought to investigate how medicinal cannabis is being represented in professional medical publications. The precis is simple. Background. Conclusions. Background.
Cannabis Law Report
JULY 15, 2022
The first Australian company to be licensed to cultivate and manufacture medicinal marijuana has praised the Federal Government’s plan to allow exports of cannabis-based medicines. “It’s very important from our perspective to ensure that the Australian patient gets medicine first. The ABC reported back in 2018.
Cannabis Law Report
DECEMBER 30, 2019
State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.
Expert insights. Personalized for you.
59 
Let's personalize your content